Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Eledon Pharmaceuticals Inc ELDN

Healthcare Biotechnology
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ELDN)

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

GlobeNewswire March 28, 2024

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

GlobeNewswire March 25, 2024

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

GlobeNewswire March 21, 2024

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 13, 2024

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

GlobeNewswire January 4, 2024

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 4, 2023

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

GlobeNewswire November 29, 2023

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

GlobeNewswire November 9, 2023

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

GlobeNewswire November 8, 2023
View More News ››

Opinion & Analysis (NDAQ:ELDN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ELDN)

Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way i

NEWS: $ELDN Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage GainEledon Pharmaceuticals,...
whytestocks - 2 days ago

ELDN - Thursday Rundown, Friday Expectations

<< View Post To Watch Video >>
HDavis - November 11, 2021

Is a Cure for Diabetes Being Studied

Is a Cure for Diabetes Enetering Phase II Trials? https://www.channelchek.com/news-channel/Is_a_Cure_for_Diabetes_Being_Studied_
SmallCapPaul - December 11, 2020

Functional Cure for T1D Discussion

Noble Capital Markets, Inc. Announces Type-1 Diabetes Day- The Beginning of the End; Close to a Cure?   A Panel of World...
SmallCapPaul - November 23, 2020

Novus Acquires Anelixis Therapeutics

Acquisition includes lead clinical-stage compound AT-1501, a next generation anti-CD40L antibody, in development for organ and cellular...
schoolofrock - September 15, 2020

Nice Move Today

This should be a good one. Phase 1 but very promising imho.
dmacd - January 22, 2019
View more Bullboard ››

Western Exploration Inc

Western Exploration Inc

Western Exploration Inc. is focused on gold and silver discoveries in Northern Nevada. The Company is engaged in the business ...
View More »